Schedule 13D ownership disclosure
VERRICA PHARMACEUTICALS INC
Common Stock, par value $0.0001 per share · CUSIP: 92511W207
Event date: 2025-12-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Caligan Partners LPReported CIK 0001727492
Shares: 6,503,054.00 · Class: 9.99%
- David JohnsonReported CIK 0001785557
Shares: 6,503,054.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-005417
- Form type
- SCHEDULE 13D/A
- Filer
- Caligan Partners LP
- CIK
- CIK 1727492
- Filed
- Dec 30, 2025
- Reporting period
- Dec 26, 2025
- Description
- Schedule 13D beneficial ownership